TENX NASDAQ
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Chapel Hill, NC 27517
US
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| ADAR1 Capital Manage | P-Purchase | 331,979 | $1.66 | 2026-10-21 |
| ADAR1 Capital Manage | P-Purchase | 254,342 | $1.60 | 2026-10-20 |
| ADAR1 Capital Manage | P-Purchase | 336,528 | $1.51 | 2026-10-19 |
| Doogan Declan | P-Purchase | 53,000 | $1.92 | 2026-09-16 |
| Giordano Christopher | P-Purchase | 4,850 | $1.82 | 2026-09-15 |